Gain Therapeutics, Inc. (GANX) AI Stock Analysis

Gain Therapeutics, Inc., established in 2017 and headquartered in Bethesda, Maryland, is a biotechnology firm with 20 employees. The company specializes in therapies for rare genetic disorders and neurological conditions stemming from protein misfolding. Using its proprietary Site-Directed Enzyme Enhancement Therapy platform, Gain Therapeutics identifies allosteric sites on misfolded proteins and develops small molecules to restore proper protein folding. Its pipeline of structurally targeted allosteric regulator candidates targets conditions such as GBA1-linked Parkinson's disease, Morquio B syndrome, GM1 gangliosidosis, neuronopathic Gaucher disease, Krabbe disease, and Mucopolysaccharidosis type 1.

Gain Therapeutics reported revenue of $41,301 in FY2019, $28,881 in FY2020, $164,994 in FY2021, and $140,108 in FY2022, before revenue fell 60.6% to $55,180 in FY2023. Over the 5-year period from FY2018 to FY2023, revenue had a compound annual growth rate of 21.8%. Net losses expanded from -$2.2M in FY2019 to -$22.3M in FY2023, while research and development expenses grew from $1.6M in FY2019 to $11.5M in FY2023. For the trailing twelve months ending June 30, 2026, revenue stood at $0, with quarterly revenue falling 100.0% year-over-year. Diluted EPS for FY2023 was -$1.78, compared to -$0.50 over the trailing twelve months.

As of June 30, 2026, Gain Therapeutics held $13.1M in cash and short-term investments against total debt of $609,874, resulting in net cash of $12.5M. The company reported total assets of $15.4M and shareholders' equity of $11.3M, yielding a debt-to-equity ratio of 0.05 and a current ratio of 4.36. Free cash flow was -$18.9M in FY2023, reflecting ongoing operating cash burn of -$18.9M. In FY2025, capital expenditures were $2, and the company's share count increased 321.8% over the past 5 years.

Gain Therapeutics carries a market capitalization of $55.0M and an enterprise value of $68.0M. The stock trades at a price-to-book ratio of 7.1x, a price-to-sales ratio of 255.5x, and an EV-to-revenue ratio of 138.3x. In comparison, the median of its US-listed Healthcare peers trades at a price-to-sales ratio of 4.1x and an EV-to-EBITDA ratio of 12.0x. As of October 16, 2026, the stock closed at $1.26, having fallen 30.4% over the prior year and 60.9% year-to-date, trailing the S&P 500 (SPY) 1-year gain of 16.8%.

Wall Street coverage for Gain Therapeutics includes 4 Strong Buy ratings and 1 Buy rating, with 0 Hold or Sell ratings. The mean price target is $7.20, representing an upside of 471.4% from the last close of $1.26 on October 16, 2026. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $0 and an EPS of -$0.51. For the following fiscal year, 4 analysts project revenue of $0 and an EPS of -$0.69. Gain Therapeutics has beaten EPS estimates in 3 of the last 4 quarters, with its next earnings date scheduled for November 11, 2026.

This page is an AI-written research summary of Gain Therapeutics, Inc. (GANX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: GANX income statement, GANX balance sheet, GANX key metrics, GANX analyst forecast, GANX chart. See the GANX stock overview for the latest quote and news.